Neumora seeks deals to expand neuro pipeline as CEO leverages M&A experience

Neumora Therapeutics, a brain disease biotech born out of stitching together multiple neuroscience startups, is looking to replicate its original playbook by complementing its seven-drug pipeline with external assets thanks to a September IPO and $520 million balance sheet.

The drugmaker already has its hands full with a Click here to view original post